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Aldose reductase is a NADP(H)-dependent enzyme, believed to be strongly implicated in the
development of degenerative complications of Diabetes Mellitus. The search for specific
inhibitors of this enzyme has thus become a major pharmaceutic challenge. In this study, we
applied both X-ray crystallography and mass spectrometry to characterize the interactions
between aldose reductase and four representative inhibitors: AminoSNM, Imirestat, LCB3071,
and IDD384. If crystallography remains obviously the only way to get an extensive description
of the contacts between an inhibitor and the enzymatic site, the duration of the crystallographic
analysis makes this technique incompatible with high throughput screenings of inhibitors. On
the other hand, dissociation experiments monitored by mass spectrometry permitted us to
evaluate rapidly the relative gas-phase stabilities of the aldose reductase-inhibitor noncovalent
complexes. In our experiments, dissociation in the gas-phase was provoked by increasing the
accelerating voltage of the ions (Vc) in the source–analyzer interface region: the Vc value
needed to dissociate 50% of the noncovalent complex initially present (Vc50) was taken as a
gas-phase stability parameter of the enzyme-inhibitor complex. Interestingly, the Vc50 were
found to correlate with the energy of the electrostatic and H-bond interactions involved in the
contact aldose reductase/inhibitor (Eel-H), computed from the crystallographic model. This
finding may be specially interesting in a context of drug development. Actually, during a drug
design optimization phase, the binding of the drug to the target enzyme is often optimized by
modifying its interatomic electrostatic and H-bond contacts, because they usually depend on
a single atom change on the drug, and are easier to introduce than the hydrophobic
interactions. Therefore, the Vc50 may help to monitor the chemical modifications introduced in
new inhibitors. X-ray crystallography is clearly needed to get the details of the contacts and to
rationalize the design. Nevertheless, once the cycle of chemical modification is engaged, mass
spectrometry can be used to select a priori the drug candidates which are worthy of further
crystallographic investigation. We thus propose to use the two techniques in a complementary
way, to improve the screening of large collections of inhibitors. (J Am Soc Mass Spectrom
1999, 10, 635–647) © 1999 American Society for Mass Spectrometry
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Although the physiological role of aldose reduc-tase (AR) (EC 1.1.1.21) in healthy individuals isstill a matter of debate, it is believed to be of
primary importance in the development of severe de-
generative complications of Diabetes mellitus, through its
ability to reduce excess D-glucose into D-sorbitol in
noninsulinodependent tissues [1]. In vitro, aldose reduc-
tase has been shown to act on a wide range of sub-
strates, such as aldehydes, aldoses, or corticosteroids,
but it is most effective on steroid hormones [2], as
confirmed by a recent report [3]. This NADPH-depen-
dent enzyme reduces a carbonyl oxygen to a hydroxyl,
in an ordered bi–bi mechanism, where NADPH is
bound first and NADP1 released last. Like all other
NADP-dependent enzymatic reactions known to date,
this reduction is stereospecific with respect to the coen-
zyme. Upon formation of the enzyme–coenzyme–sub-
strate ternary complex, a hydride is transferred from
the C4 carbon atom of the nicotinamide ring (4-pro-R,
A-face) of NADPH [4, 5] to the carbonyl carbon of the
substrate, while a proton is provided by the enzyme to
the carbonyl oxygen.
Several crystallographic analyses have been per-
formed on this enzyme. These include the solution of
the structure of the apoenzyme from pig lens [6] and of
the human [7, 8] and pig holoenzymes [9]. They have
revealed that aldose reductase folds in a (b/a)8 barrel,
and that the catalytic site lies at the bottom of a deep
hydrophobic cleft.
Because inhibition of aldose reductase is thought to
be a way of avoiding the complications of diabetes, the
search for inhibitors of this enzyme has become an
important pharmaceutical goal. A large variety of struc-
turally diverse compounds have been identified as
potent in vitro aldose reductase inhibitors, and are
studied to develop new drugs.
However, only a small part of them have demon-
strated a good in vivo level of activity and have proved
their efficiency in preventing the development of dia-
betic complications in animals and humans [10]. These
in vivo active compounds are usually classified in two
major structural classes: spirohydantoins, such as Sor-
binil [11] or Alconil [12], and carboxylic acids, such as
Ponalrestat [13], Zopolrestat [14], or Tolrestat [15]. This
last inhibitor is one of the most intensively studied from
the pharmaceutical point of view, including large scale
trials [16]. In addition to these two wide classes of
aldose reductase inhibitors, a third class is now emerg-
ing: the sulphonylnitromethane derivatives, such as
ICI215918 [17] and AminoSNM [18].
In this context, crystallographic studies of several
aldose reductase–inhibitor and aldose reductase–sub-
strate complexes were undertaken in the last few years,
in order to improve the knowledge of the interactions
involved in the enzyme–coenzyme–inhibitor com-
plexes, and consequently to help the design of specific
inhibitors. These studies include the crystal structure
determination of the complexes with the inhibitors
Zopolrestat [19], Alrestatin [20], Tolrestat, and Sorbinil
[21] and with the substrates citrate, cacodylate, and
glucose 6-phosphate [22].
The X-ray diffraction data provided a detailed de-
scription of the interatomic contacts involved in these
complexes, and it appeared that all these molecules
bind in the active site of the holoenzyme, and recognize
a specific anionic site delineated by the C4N of the
nicotinamide ring, the Oh of Tyr48 and the Ne of
His110. This anionic site can be divided in three sepa-
rate centers, each occupied by one inhibitor atom [21].
In some cases (e.g., in the cases of Tolrestat, of Zopol-
restat, and of a second Alrestatin molecule), additional
interactions occur in a pocket accessible only after a
conformational change of the protein: this pocket is
responsible for the specific recognition of the inhibitors
by aldose reductase, among the enzymes of the aldo–
ketoreductase family. The information provided by the
detailed X-ray diffraction studies is expected to help the
design of new inhibitors, with improved affinities for
the enzyme.
Yet, a problem when testing inhibitors by X-ray
crystallography is the duration of the crystallographic
study; therefore, it is of interest to develop a method-
ology which could rapidly supply information about
how inhibitors interact. This methodology would allow
the screening of large collections of inhibitors and the
selection of the most interesting ones for a further study
by X-ray crystallography.
In this sense, we hereby present the utility of elec-
trospray ionization mass spectrometry (ESI-MS) [23] to
provide both preliminary and complementary informa-
tion on aldose reductase/inhibitor interactions to that
obtained by X-ray diffraction, from less material and in
a shorter time frame.
In classical molecular mass spectrometry, ESI is
widely used for purity evaluation and characterization
of biomolecules such as proteins and recombinant pro-
teins [23, 24], essentially because this ionization mode
permits one to measure the molecular mass of these
large entities with a high accuracy (better than 0.01%)
and a high sensitivity [25].
Besides the classical molecular mass spectrometry,
the field of supramolecular mass spectrometry has
expanded rapidly in recent years: mass spectrometry,
and especially ESI-MS, has been used to study su-
pramolecular edifices formed by noncovalent interac-
tions [26]. In fact, the weak intermolecular interactions
involved in these supramolecular complexes were sur-
prisingly shown to survive the ESI process. ESI-MS thus
allowed the intact complexes to be detected and mea-
sured after their complete desolvation.
ESI-MS, for example, is today routinely used to
determine the stoichiometry of synthetic supramol-
ecules with coordinated metal ions [27–29], or even a
few hydrogen bonds [30]. It has also permitted one to
elucidate self-assembly processes [31] and/or cooperat-
ivity phenomena [32] involved in the formation path-
ways of these synthetic supramolecular edifices.
Similar applications of ESI-MS were also reported in
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the field of biological supramolecular complexes. A first
example of intermolecular noncovalent interactions in-
volving biological species and investigated by ESI-MS
was given by Ganem in 1991 [33]. After this first study,
the methodology has been improved and ESI-MS has
been successfully used to determine the stoichiometry
of many protein-protein complexes [34–37], protein–
ligand complexes [38, 39], polypeptide–metal ion com-
plexes [40, 41] or protein–DNA interactions [42, 43]. In
particular, the ability of ESI-MS to investigate the non-
covalent complexes of aldose reductase (i.e., the dimeric
form of the apoenzyme, as well as the enzyme–coen-
zyme and enzyme–coenzyme–inhibitor complexes) has
been demonstrated in earlier studies [44, 45]; it is
interesting to note that the results obtained by Jaquinod
et al. and Potier et al. were found perfectly consistent
with the detailed information later obtained on the
same complexes by X-ray crystallography.
All the studies referenced above and others [46–48]
show that important structural features are retained in
the gas phase, where the protein is dried in vacuo.
Nevertheless, if most of the electrostatic interactions
and hydrogen bonds seem to survive the ESI process,
the hydrophobic interactions are believed to be partly
lost in the gas phase [49, 50]. Therefore, there is not
always a direct correlation between the gas-phase sta-
bility and the solution-phase stability of protein–ligand
noncovalent complexes, and the usefulness of ESI-MS
experiments to investigate the solution-phase binding
properties is debated [51–53].
In the present study, we thus focused on under-
standing the thermodynamic significance of the gas-
phase stabilities, as measured by ESI-MS, in order to use
directly the gas-phase information to characterize the
enzyme/inhibitor interactions existing in solution. This
was achieved by a parallel study of aldose reductase–
coenzyme–inhibitor complexes by ESI-MS and X-ray
crystallography. The results are presented in this paper
for four inhibitors (Figure 1), selected to be representa-
tive of the different structural families described before:
Imirestat, which belongs to the spirohydantoins family;
LCB3071, representative of the carboxylic family; Amin-
oSNM, extracted from the last class identified: the
sulfonylnitromethane derivatives; and IDD384 (IDD,
personal communication), a glycine analog of the sul-
fonylnitromethane derivative ICI215918, which can be
considered as an “hybrid” of carboxylic acids and
sulfonylnitromethane.
Our study revealed that, besides the obviously much
more precise X-ray diffraction data, the rapidly avail-
able gas-phase measurements may be very helpful to
get information about the type and the strength of the
interactions developed by an inhibitor in the active site
of aldose reductase. These two different approaches:
X-ray crystallography and mass spectrometry, permit-
ted a better understanding of the bioisosteric equiva-
lence between the sulphonylnitromethanes, and, re-
spectively, the spirohydantoins and carboxylic acid




Purification and crystallization of the pig holoenzyme. Pig
eyes collected from freshly slaughtered animals were
immediately frozen on dry ice. The lenses were ex-
tracted, frozen on dry ice, and stored at 20°C until used.
D-xylose, dithioethreitol (DTT), and MES were obtained
from Sigma or Boehringer-Mannheim, NADP and
NADPH from Boehringer-Mannheim, xylitol from Al-
drich Chemicals, polyethylene glycol (PEG) 3000 and
6000 and EDTA from Fluka.
The purification [54] was performed at 4°C and all
the buffers were degassed with argon. Pig lenses (100 g)
were homogenized in a Waring blender for 2 min in 50
mM phosphate buffer pH 7.0, 1 mM EDTA, 5 mM DTT,
0,002% chlorhexidine (buffer A) (200 mL). The homog-
enate was centrifuged at 10000 rpm for 90 min. The
supernatant was brought to a 30% (w/v) concentration
of PEG 3000 by adding 1.0 vol of a 60% (w/v) PEG 3000
solution in buffer A and stirred for 1 h under argon.
After centrifugation as above, the supernatant was
diluted with water (600 mL) and loaded on a DEAE 50
Sephadex column (200 mL, equilibrated with 20 mM
phosphate buffer pH 7.0, 1 mM EDTA, 1 mM DTT:
buffer B). The elution was performed first with buffer B
(500 mL) and then with a gradient of buffer B (600 mL)
Figure 1. Chemical formulas of the four inhibitors, LCB3071,
Imirestat, AminoSNM, and IDD384, used in this work. The chosen
protonation of the carboxylate inhibitors, IDD384 and LCB3071,
and the chosen resonance state of Imirestat correspond to the
models used in the calculations.
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and of 0.5 M phosphate buffer pH 7.0, 1 mM EDTA, 1
mM DTT (600 mL). The flow rate was 20 mL/h and
fractions of 10 mL were collected. The fractions with the
highest activity were concentrated with an Amicon PM
10 membrane. The concentrated fractions were dialyzed
against 25 mM MES buffer pH 6.2, 1 mM EDTA and 5
mM DTT (three times 1 L) and concentrated in Centri-
con PM 10 microconcentrators (Amicon).
The crystals of holoenzyme were grown by the
hanging drop method by vapor diffusion with PEG
6000. The drop concentration was 15 mg/mL of aldose
reductase, two equivalents of NADP1 in 75 mM MES
buffer pH 6.2, 1 mM EDTA, 1 mM DTT, 2.5% PEG 6000
(w/v) and the well concentration was the same buffer
25% PEG 6000. Suitable crystals were obtained within
10 days.
Soaking with inhibitors. The complexes with the inhib-
itors were obtained in the following way: the crystals
were transferred to a capillary. The mother liquor was
removed and a solution containing the inhibitor was
added [120 mM TES buffer pH 6.2, 1 mM EDTA, 1 mM
DTT, 30% PEG 6000 (w/v), 10 mM sorbinil or 62 mM
tolrestat]. Crystals were placed in a solution at 5
mg/mL during a 5 h period for the following inhibitors:
Imirestat, AminoSNM, LCB3071, and IDD384.
Data collection and structure determination. The space
group was P43212, with one monomer per asymmetric
unit. Data were collected from one crystal mounted on
a synchrotron source, using a MARS image plate, and
treated with the MARXDS package [55]. For each inhib-
itor complex, the position of the protein was deter-
mined by rigid body refinements using the program
X-PLOR [56] at 3 Å, with the structure of the native
enzyme as starting model [21]. The resulting model was
used to calculate density maps of the type Fobs-Fcalc and
2Fobs-Fcalc. For each complex, the maps clearly revealed
the electron density corresponding to the presence of
one inhibitor molecule in the active site. This density
corresponded to the whole inhibitor, except in the case
of IDD384, which has an ordered part with a clear
crystallographic signal and a more disordered part. The
initial 2Fobs-Fcalc maps are shown in Figure 2. The
inhibitors were then built into the electron density with
the program O [57] on a Silicon Graphic station, and the
whole complex was refined using the program X-PLOR
[56]. The resolution was gradually increased to the limit
of the observable data. Solvent molecules were gradu-
ally included from Fobs-Fcalc and 2Fobs-Fcalc electron
density maps if the peak heights were stronger than 2s,
and the positions were near suitable hydrogen bonding
donors or acceptors. Further positional refinements and
individual constrained temperature B-factor refine-
ments of the entire structure led to the final models (see
Table 1 for details of data collection and refinement
statistics).
Calculations of electrostatic and H-bond binding energy
terms. We made a first approximate calculation of the
electrostatic and H-bonds components of the binding
energy involved, assuming that, upon inhibitors bind-
ing, residues Tyr48, His110 and Trp111 of aldose reduc-
tase act as H-bond donors, while the acidic moieties in
the hydrophilic heads of the inhibitors act as H-bond
acceptors. The calculations were done with X-PLOR
[56], and the charge states of the inhibitors were calcu-
lated ab initio with SPARTAN [58]. All the electrostatic
and H-bond interactions inhibitor–protein were taken
into account. For Imirestat, the tautomer (shown in
Figure 1) with the largest binding energy was chosen.
For LCB3071 and IDD384, we assumed that the acidic
group was in the -COO2 form. For aldose reductase,
following the results of the native crystal structure at
1.0Å resolution (to be published elsewhere), the His110
residue was assumed to be protonated at the Ne2
position. The CHARMM set of partial charges was
employed [59] except for the OH group of Tyr48, where
the polarization by nearby Lys77 was taken into ac-
count. This force field reproduces the sublimation and
vaporization energies of small organic compounds [60],
and it is therefore well adapted for this case where the
experiment is done in vacuo. More detailed calculations
using quantum mechanics are underway and will be
published elsewhere.
Mass Spectrometry
Instrument. Mass spectrometric studies were per-
formed on a VG BioQ triple quadrupole mass spectrom-
eter (Micromass), upgraded to Quattro II performances.
The first quadrupole has a mass-to-charge (m/z) ratio
range of 4000, while the second analyzer has a m/z range
of 8000. In this work, ions were detected below m/z
4000, at the exit of the first analyzer.
ESI conditions were optimized in order to preserve
the noncovalent complexes during the ionization–des-
orption process, while keeping a sufficient desolvation
to ensure a good sensitivity and a good resolution.
Basically, two parameters were concerned: the pressure
in the first stage of the atmosphere–vacuum interface
(“interface region”), and the accelerating cone voltage
(Vc), which determines the electrostatic field in this
region. On our instrument, a skimmer lens of small
diameter enables one to set the pressure in the interface
region at a high value (up to 4 mbar, instead of 1.2 mbar
on the standard instrument), while keeping a correct
pressure in the analyzer (,2.1026 mbar). The high
pressure in the interface region is of crucial importance
for the detection of intact noncovalent complexes.
Moreover, it permits one to tune the Vc voltage at
relatively high values (60–115 V), while preserving the
noncovalent interactions. Since Vc strongly influences
the desolvation of the ions, this allows an improved
sensitivity and an improved peaks resolution.
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Relative gas-phase stabilities of enzyme–coenzyme–inhibitor
complexes. Relative stabilities of noncovalent enzyme–
coenzyme–inhibitor complexes in the gas phase were
evaluated by CID-MS (CID: collision-induced dissocia-
tion) experiments. In these experiments, the dissocia-
tion of the noncovalent edifice is caused by energetic
collisions occurring with gaseous molecules in the in-
terface region of the mass spectrometer, where the
pressure is still relatively high (1 to 4 mbar). The
resistance shown by a noncovalent complex to these
collisions reflects its gas-phase stability.
The energy transferred to the noncovalent edifice
during the collision, from which will depend the occur-
rence of the dissociation, can be controlled by the Vc
voltage. This voltage determines the electrostatic field
reigning in the interface region, and therefore, the
kinetic energy acquired by the noncovalent edifice
when it collides with other gaseous molecules. For each
complex, Vc was increased in order to produce 50% of
the enzyme–coenzyme–inhibitor complex dissociation
into enzyme–coenzyme and inhibitor separate species.
The corresponding Vc value, which we named Vc50,
was considered as a gas-phase stability parameter of the
complex. It must be noted that the energy of the
collisions is also strongly influenced by the pressure in
the interface region. For the measurement of the Vc50,
this pressure was kept constant and equal to 2 mbar.
The reproducibility of the Vc50 measurements was
evaluated by comparing the Vc50 obtained for the
Tolrestat (which is the most studied inhibitor of aldose
reductase) from more than ten series of measurements
performed under identical experimental conditions. We
got a reproducibility of the Vc50 values of 62 V, from
measurement to measurement (same day), from day to
Figure 2. Electron density maps (2Fobs-Fcalc, acalc) calculated
from the protein model only, after rigid body refinement, con-
toured at 1s value. These maps show clearly the position of the
inhibitor, with the exception of the part of IDD384 furthest from
the catalytic site, which is likely to be disordered.
Table 1. Data collection and refinement statistics
Inhibitors LCB3071 Imirestat AminoSNM IDD384
Space group P43212 P43212 P43212 P43212
Unit cell: a,c (Å) 68.5, 153.9 68.1, 153.1 68.2, 153.2 68.7, 154.5
Diffraction data
d min (Å) 2.0 2.0 2.3 2.6
Unique reflections (N) 25277 25854 16257 11679
Completeness (%) 98.9 97.5 97.4 94.4
Rigid body refinement
Resolution (Å) 8.0–3.0 8.0–3.0 8.0–3.0 8.0–3.0
Rcryst 26.8 27.1 28.3 23.7
Refinement
Resolution (Å) 8.0–2.0 8.0–2.0 8.0–2.3 8.0–2.6
Reflections used 21188 (4sF) 23718 (2sF) 15444 (2sF) 9626 (2sF)
Rcryst/Rfree 21.0/27.8 22.2/28.5 19.3/27.6 17.9/27.2
Final model
Protein residues 315 315 315 315
Coenzyme 1 1 1 1
Inhibitor 1 1 1 1
Water molecules 194 225 143 25
rms deviations
Bonds (Å) 0.007 0.007 0.007 0.007
Angles (°) 1.41 1.44 1.45 1.43
Dihedrals (°) 27.52 27.61 27.96 27.88
Impropers (°) 0.70 0.70 0.71 0.68
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day (over more than four months), and from one
enzyme sample to another (more than four batches
tested). In order to reach a good reproducibility from
day to day, it is necessary to work under strictly
identical pressure conditions in the interface. In our
instrument, the pressure can only be regulated with an
accuracy of 0.1 mbar. Therefore, we used the pressure
that gives a Vc50 of 85 V for the Tolrestat as a baseline.
Thanks to this daily adjustment, we obtained a better
reproducibility in the Vc50 measurements of the four
inhibitors presented in this study (61 V).
The mass spectra are the average sum of 12 scans
from m/z 2400 to 4000, at a scan rate of 8 s/scan.
Calibration of the instrument was performed using the
multiply charged ions produced by egg white lysozyme
(Sigma) dissolved at 20 mM in water.
Sample preparation. Mass spectrometric studies were
performed on both the pig lens and the recombinant
human aldose reductase for a large variety of inhibitors.
Both enzymes exhibit a similar behavior in ESI-MS
analysis (data not shown). In particular, identical
charge states distributions were observed for the two
enzymes on the ESI spectra, which indicates that they
fold in a comparable manner [61]. Furthermore, we
verified with several inhibitors that the enzyme–coen-
zyme–inhibitor complexes displayed similar gas-phase
stabilities with the porcine or with the human enzyme
(this similarity was expected, since the two enzymes
have a strong primary sequence homology: more than
85% of the amino acids are identical between the two
enzymes; in particular, the amino acids in the active site
cleft are all conserved).
As the use of a human source of aldose reductase
seems more adequate in terms of drugs design against
degenerative complications of Diabetes Mellitus in hu-
mans, and as the recombinant enzyme is available in
larger quantities and with a higher purity than the
enzyme purified from pig lenses, it was usually pre-
ferred to the pig lens aldose reductase for the evaluation
of large collections of inhibitors by ESI-MS.
Pig lens aldose reductase (MW 5 35778 Da) was
purified as described before. Recombinant human al-
dose reductase was cloned from human placenta [62]
and overexpressed in E. Coli. Its primary sequence was
verified through LC-MS analysis (liquid chromatogra-
phy coupled to mass spectrometry). All the peptides
obtained after digestion by Endoproteinase LysC
(Boehringer, Mannheim) were identified and had the
expected mass. Further sequence verifications were
performed by Edman degradation. The recombinant
protein was produced as an hexahistidine-tagged pro-
tein, to facilitate the purification steps. After removal of
the 6His-TAG, aldose reductase was obtained with four
amino acids at its N-terminus, which are not present in
the in vivo protein: three amino acids remaining from
the 6His-TAG (Gly-Ser-His), and a Met, which is ex-
cised in vivo. The mass measured by ESI-MS for the
recombinant human aldose reductase (MW 5 36138 6
1.2 Da) fits well with the expected mass, taking into
account these four supplementary amino acids (MW 5
36136 Da). Details of the expression of the human
enzyme will be published elsewhere.
Both pig lens and recombinant human enzymes were
desalted prior to ESI-MS experiments using Centricon
PM 10 microconcentrators (Amicon). The formation of
the noncovalent complexes in solution was achieved by
incubating human aldose reductase (10 mM in 10 mM
ammonium acetate, pH 7.0) with one mol/mol of
cofactor (NADP1) and one mol/mol of inhibitor, for a
few minutes, at room temperature. Samples were then
continuously infused into the ion source of the mass
spectrometer at a flow rate of 5 mL/min.
Results
Crystal Structures of the Complexes with
Inhibitors AminoSNM, Imirestat, LCB3071 and
IDD384
Figure 1 gives the chemical structure of the inhibitors
studied in this paper. All have a hydrophilic head and
a hydrophobic body.
Binding to the catalytic site and other electrostatic interac-
tions. As shown by the results of X-ray diffraction
analysis, presented in Figures 2 and 3 and in Table 1, the
binding of the inhibitors to the catalytic site follows the
pattern already described for Zopolrestat, Tolrestat, and
Sorbinil [21]: the hydrophilic heads of the inhibitors
bind the active site cleft delineated by Tyr48, His110,
and Trp111. The case of LCB3071 is like the one of
Tolrestat, with two binding sites, while the case of
Imirestat is like the one of Sorbinil, with three binding
sites. In the case of AminoSNM, the NO2 oxygens bind
strongly His110 and Tyr48, while the SO2 oxygens bind
His110 and Trp111. In the case of IDD384, there is a
strong binding of one CO2 oxygen to both His110 and
Tyr48, while again one SO2 oxygen binds Trp111.
The exact identification of the H-bond donors and
acceptors requires the knowledge of the protonation
state of both the protein and the inhibitor; in the case of
Imirestat, this also determines the tautomer present in
the catalytic site. As discussed in previous papers for
the cases of Tolrestat [21] and Zopolrestat [19], the
COOH hydrophilic head of LCB3071 and IDD384
should be in the -COO2 form at the pH of the mother
liquor (pH 6.2 for pig aldose reductase) and of the mass
spectrometric studies (pH 7.0). Since the short distances
(around 2.5 Å) between Ne2 of His110 and the carbox-
ylate oxygens of LCB3071 and IDD384 imply an H-
bond, and the carboxylate is not protonated, we deduce
that His110 is protonated at the Ne2 position. This
conclusion is reinforced by the structure of AminoSNM,
since again, the H atom for the H-bond (d 5 2.57 Å)
between the -NO2 hydrophilic inhibitor’s head and the
Ne2 atom of His110 is necessarily given by the protein.
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Figure 3. Contacts of the inhibitors hydrophilic heads to the catalytic site of the protein. Note that the
hydrogen bonds with Tyr48, His110, and Trp111 are mostly responsible for the binding with this part
of the protein.
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In the case of Imirestat, which is neutral at pH 6.2, the
situation is similar to the one of Sorbinil [21], where the
inhibitor is in a tautomeric state (see Figure 1) where the
nitrogen atom between the oxygens has a lone pair of
electrons, and makes an H-bond with His110. Note that
these results about the protonation state concern the
holoenzyme with NADP1. For the case of the active
holoenzyme with NADPH, Lee et al. [63] have made
quantum mechanical modeling studies where they pro-
pose that His110 is doubly protonated, and therefore
charged. This conclusion is probably applicable to the
current case.
IDD384 and LCB3071 have short contacts between an
O atom of the -COO2 group and residues Tyr48 and
His110. These short contacts, together with the charges
on the acidic oxygens, should result in strong electro-
static and H-bond terms in the binding energy.
For comparison of the X-ray crystallography data
with the ESI-MS experiments performed in vacuo, we
focused on the electrostatic and H-bonds binding to the
catalytic site of aldose reductase (contacts with the
specificity pocket were not taken into account, since
they are mainly hydrophobic, and likely to be lost in the
mass spectrometric experiments where the protein is
dried in vacuo). The results are shown in the upper part
of Table 2, and are discussed below. Extended calcula-
tions, including all possible protonation states, are
currently under way.
Binding to the hydrophobic cleft. All inhibitors have a
hydrophobic body which binds to the protein. Similar
to the reported case of Sorbinil, Imirestat and Amin-
oSNM bind the hydrophobic cleft with very little con-
formational changes of the protein. Like Tolrestat,
LCB3071 binds the specificity pocket, which is accessi-
ble only after a conformational change of aldose reduc-
tase [21]. In the case of IDD384, the first ring binds to
the active site cleft, while the last six-member ring is
flexibly linked to the main body of the molecule: the
available space on top of the active site cleft allows for
several positions of this last ring, therefore explaining
its disorder.
The results described above confirm the finding of
the previous paper [21] concerning the two modes of
binding, one to the specific pocket and the other to the
active site cleft. This information, particularly the one
concerning the binding to the specific pocket, is very
useful for current ongoing work on inhibitors of phar-
maceutical interest (to be published elsewhere).
Evaluation of the Gas-phase Stabilities by
Mass Spectrometry
Gas-phase stabilities of the noncovalent enzyme–coen-
zyme–inhibitor complexes with the inhibitors Amin-
oSNM, Imirestat, LCB3071, and IDD384 were evaluated
through CID-MS experiments. These experiments were
performed by varying the Vc voltage, which determines
the kinetic energy of the ions when they collide with
residual gaseous molecules in the interface region of the
mass spectrometer. Increasing Vc results in an in-
creased energy transferred by collision to the noncova-
lent edifice, and allows one to provoke an energetically
controlled dissociation of the complex (the pressure,
which also influences the energy of the collisions, is
kept constant).
The Vc voltage was adjusted to provoke the dissoci-
ation of 50% of the enzyme–coenzyme–inhibitor com-
plex initially present, through removal of the inhibitor.
The corresponding Vc value, designated as Vc50, re-
flects the gas-phase stability of aldose reductase–coen-
Table 2. List of the electrostatic and H-bond contacts of the inhibitor’s O and N atoms in the catalytic site (these contacts are shown
graphically, together with the exact distance, in Fig. 3). The calculated electrostatic and H-bond energies associated with these
contacts are given (Eel-H), as well as the gas-phase stabilities experimentally measured by mass spectrometry (Vc50 values), and the
binding energies measured in solution (IC50). Clearly, the sum of the energies of the electrostatic and H-bond interactions, calculated
from the crystallographic data (Eel-H), lead to the same classification of the four inhibitors than the gas-phase stability measured by
ESI-MS (Vc50). On the contrary, it is obvious that Vc50 and the IC50 do not lead to the same classification of the inhibitors.
AminoSNM Imirestat LCB3071 IDD384
X-ray crystallography
H bond , 3.0 Å O . . . H–O(Y48) O . . . H–O(Y48) O . . . H–O(Y48) O . . . H–O(Y48)
O . . . H–O(Y48) N . . . H–N(H110) O . . . H–N(H110) O . . . H–N(H110)
O . . . H–N(H110) O . . . H–N(W111) O . . . H–N(W111)
H bond . 3.0 Å O . . . H–N(H110) O . . . H–O(Y48)
O . . . H–N(W111) O . . . H–N(W111)
Energy (kcal/mol)
1: Electrostatic 214 233 281 287
2: H-bond 210 210 210 27
1 1 2: Eel-H 224 243 291 294
Mass spectrometry
Vc50 (V) 70 6 1 76 6 1 84 6 1 103 6 1
Solution phase measurement
IC50 (nM) 52 10 9 108
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zyme–inhibitor complexes, and was used to classify the
four inhibitors AminoSNM, Imirestat, LCB3071, and
IDD384, according to the gas-phase stability of their
complexes with aldose reductase.
Determination of the Vc50 from the ESI mass spectra.
Figure 4 shows the ESI mass spectra recorded at various
Vc voltages for an equimolar mixture of aldose reduc-
tase, coenzyme (NADP1), and inhibitor LCB3071. The
species at MW 5 37225 Da corresponds to the ternary
complex AR-NADP1-LCB3071, while the species at
MW 5 36880 Da corresponds to the dissociated holoen-
zyme (AR-NADP1).
As exemplified by this figure, the extent of ternary
complex dissociation is readily visualized through the
appearance of the holoenzyme species, as Vc is in-
creased from 65 to 95 V. For each Vc value, the extent of
dissociation may be calculated by measuring the abun-
dance of the holoenzyme, relative to that of the com-
plexed species. It is further expressed by the ratio:
[holoenzyme]/[ternary complex]. The abundance in
dissociated and complexed species was deduced from
the peak heights measured on the ESI mass spectra; this
deduction seems relevant here because the holoenzyme
and the complexed species (with all the inhibitors)
exhibit exactly the same peak shape and the same
charge state distribution (three charge states, the main
charge state being the 121). Note that the approach
would not have been valid if the two species had given
rise to different charge states on the mass spectra, since
they would not have displayed the same response in
ESI-MS analysis. In addition, if the charge states of the
complexed species had been different from one inhibi-
tor to another, it would have lost any significance to
compare the extent of dissociation of the two com-
plexed species at a given Vc, since the charge state
influences the collisional energy.
Figure 5 represents, for the four enzyme–coenzyme–
inhibitor complexes studied in this paper, the [holoen-
zyme]/[ternary complex] ratio as a function of Vc.
Depending on the inhibitor, the diagram shows that the
ternary complexes exhibit different sensitivities to gas-
phase collisions. The Vc50 is derived by reading the Vc
voltage corresponding to a ratio [holoenzyme]/[ternary
complex] equal to 1. The choice of a 50% dissociation to
evaluate the gas-phase stability of enzyme–inhibitor
complexes was motivated by the necessity to have both
the holoenzyme and the complexed species signifi-
cantly present on the mass spectrum, in order to get a
reliable calculation of the [holoenzyme]/[ternary com-
plex] ratio.
Table 2 reports the Vc50 values which were deduced
from Figure 5. The complex formed with IDD384 ap-
pears to be the most stable in the gas phase, insofar as
more energy (i.e., higher Vc voltage) is needed to
induce its dissociation (IDD384 remains mainly associ-
ated to the holoenzyme up to Vc 5 103 V, whereas half
of LCB3071 is released from the holoenzyme around 85
V, half of Imirestat is released around 75 V, and half of
AminoSNM is released around 70 V). For the curves on
Fig. 5, the [holoenzyme]/[ternary complex] ratio was
calculated by summing the peak heights of all three
charge states present for both the holoenzyme and the
ternary complex; we have also calculated this ratio by
focusing on the main charge state for the two species
Figure 4. Detailed gas-phase stability study of the enzyme–
coenzyme–inhibitor complex for the inhibitor LCB3071. The ter-
nary complex gradually dissociates in the gas phase when the
accelerating cone voltage (Vc) is increased. Spectra were acquired
at four accelerating cone voltages: Vc 5 65, 75, 85, and 95 V (the
pressure at the interface source-analyzer is equal to 2 mbar).
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(121), or by considering the peak areas instead of the
peak heights. In all cases, this led to identical Vc50
values, within a range of 61 V.
From the Vc50 measurements, we have thus classi-
fied IDD384 as the strongest bound inhibitor in the gas
phase, followed by LCB3071, Imirestat, and Amin-
oSNM, in that order.
Correlation between the Vc50, determined by mass spectrom-
etry, and the binding energies, computed from crystals
structure analysis. The Vc50 value is expected to de-
pend only on the electrostatic and H-bond interactions
developed by an inhibitor in the active site of aldose
reductase. The hydrophobic interactions should play a
minor role, since solvent molecules have been totally
removed in the gas-phase stability measurements. In
addition, for the case of aldose reductase, the electro-
static and H-bond interactions developed by an inhibi-
tor with the enzyme catalytic residues were shown by
X-ray crystallography not to be water-mediated, and
should be maintained in the gas phase.
One can thus hypothesize that an inhibitor develop-
ing strong interactions of electrostatic and H-bond
types with aldose reductase will display a high gas-
phase stability, i.e., a high Vc50.
The highly detailed view provided by X-ray crystal-
lography for the active site of aldose reductase occupied
by an inhibitor permitted us to measure, with a good
accuracy, the distances of the electrostatic and H-bond
interactions involved in the binding. Knowing these
distances, it was possible to make a first approximate
calculation of the energy corresponding to the electro-
static and H-bond interactions (Experimental section),
and therefore, by comparison to the Vc50 measure-
ments, to verify our hypothesis.
Table 2 lists, for the inhibitors: AminoSNM, Imires-
tat, LCB3071 and IDD384, the H-bonds contacts in-
volved in the noncovalent aldose reductase–inhibitor
complexes, classified by donor–acceptor distance, and
the electrostatic component. The values of the electro-
static (1: Eel) and H-bond (2: EH) components of the
binding energy, calculated including these contacts, as
well as the sum of these energies (Eel-H), are given.
Table 2 also reports the results of the gas-phase stability
studies performed on the same four complexes (Vc50
values). As expected from the above considerations,
there is a clear correlation between the binding energy
calculated from electrostatic and H-bond interactions
(Eel-H), and the gas-phase stabilities evaluated by the
Vc50 values. In particular, the two inhibitors having an
ionized carboxylic end (LCB3071 and IDD384), and thus
having the higher Eel-H values, also display the higher
gas-phase stability.
Therefore, our hypothesis that the gas-phase stabili-
ties of the enzyme–coenzyme–inhibitor complexes
could measure the energy of the electrostatic and H-
bond interactions developed by the inhibitor in the
enzymatic site is verified. It should be noted that there
is obviously no precise quantitative correlation between
the Eel-H values reported in Table 2 and the Vc50 values.
One reason is that, as the protein may be partially
denatured in the mass spectrometric experiments (most
likely in the loops surrounding the anionic site), the
calculation of the Eel-H term is focused on the electro-
static and H-bond interactions which are most likely to
be conserved (i.e., those between the hydrophilic head
of the inhibitor and the anionic site of the protein). We
cannot exclude that some other interactions survive the
ESI process, and, on the other hand, there are surely
interactions occurring in the gas phase between the
partially denatured protein and the inhibitor, which
cannot be modelled from the crystal state.
The first approximate calculation of Eel-H described
before allowed a qualitative classification of the inhibi-
tors, an order which agrees with that of the observed
Vc50 values. However, let us emphasize that it is too
coarse for a detailed quantitative interpretation.
Discussion
It is tempting to extend the results of the present study
to other noncovalent systems. However, the correlation
which we have established between the Eel-H term,
computed from the crystal state model, and the Vc50
values, measured by mass spectrometry, strongly de-
pends on the preservation of the 3-D structural features
required for the binding of the inhibitor upon desorp-
tion of the protein in the gas phase.
In the case of aldose reductase, the protein folds in a
Figure 5. Gas-phase stabilities of the enzyme–coenzyme–inhibi-
tor complexes for the inhibitors AminoSNM, Imirestat, LCB3071,
and IDD384. Dissociation in the gas phase was performed through
CID-MS experiments, by increasing the accelerating cone voltage
(Vc). The ratio [holoenzyme]/[ternary complex] was calculated
by summing the peak heights of all charge states present on the
ESI mass spectra, for each species. Spectra were recorded for Vc
ranging from 60 to 115 V, at a constant pressure in the interface
source-analyzer (2 mbar).
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(b/a)8 barrel, which mainly consists of H-bond interac-
tions [6]. We could thus expect that the main structural
features would be maintained in the gas phase. How-
ever, this will surely not be the case for systems where
hydrophobicity plays a major role. Therefore, before
using a similar approach to study another protein–
ligand system, it is necessary to verify that the confor-
mation of the protein has not been dramatically modi-
fied upon desorption in the gas phase.
Our study shows that mass spectrometry may be
used to rapidly evaluate the electrostatic and H-bond
specific contacts involved in the binding of an inhibitor
to the enzymatic site of a target protein. In a context of
drug development, this may be of outmost interest to
monitor the drug design optimization phase. Actually,
once the drug design cycle is engaged, the optimization
phase often consists in modifying the interatomic elec-
trostatic and H-bond interactions developed by the
drug with the target enzyme. Since these interactions
often depend on a single atom change or addition on
the inhibitor, they are easier to introduce than the
hydrophobic ones. The possibility to measure, via the
Vc50, changes in electrostatic and H-bond contacts
upon chemical modification of the inhibitor is thus
specially adapted to monitor the drug design optimiza-
tion process.
Our assumption that gas-phase stabilities reflect the
electrostatic and H-bond contacts, to the exclusion of
hydrophobic interactions, is reinforced by the compar-
ison (Table 2) between the Vc50 and the values of the
IC50 of the inhibitors (IC50: concentration of inhibitor
giving 50% of inhibition in solution). It is striking that,
for these four inhibitors of different structural families,
the IC50 values do not follow the order of the Vc50
values.
The binding energy in solution, measured by the
IC50, may be divided in two components: an enthalpic
part, in which are included the electrostatic and H-bond
interactions, and an entropic part, mainly produced by
hydrophobicity, while the gas-phase stabilities (Vc50)
only depend on the enthalpic part. An inhibitor like
IDD384, which has a poor hydrophobic interaction with
aldose reductase (contrary to LCB3071, for instance),
displays a low inhibition capacity in solution (IC50 5
108 nM). Yet, since its binding mainly consists in
electrostatic and H-bond interactions (as proved by the
crystallographic studies), it displays the highest gas-
phase stability (Vc50). The analysis of these strong
electrostatic interactions was very useful for obtaining
potent inhibitors which are now under development.
The IC50 will surely continue to be the most impor-
tant criterium to orientate the design, since it gives the
key information about the inhibition level of a drug.
However, the example of IDD384 shows that the IC50
are not always adequate to monitor the effects of
chemical changes during a drug design optimization
process. Let us add that, within the same structural
family, the hydrophobic component in the binding
energy may be very similar from one inhibitor to
another. In this case the Vc50 values and the IC50 values
will give the same classification of the inhibitors [45].
Finally, our results help one to understand the discrep-
ancies reported by some authors [49, 50] between the
gas-phase stabilities and the solution-phase binding
affinities.
If ESI-MS appears as a promising method to monitor
the binding of inhibitors according to their electrostatic
and H-bond interactions, X-ray crystallography is still
the only way to get a detailed view of all interatomic
contacts involved in the binding, and the IC50 measure-
ments will surely remain the most important measure-
ment of the potency of a drug. We thus propose to use
all these methods in a complementary approach to
improve the efficiency of the drug design process: the
IC50 measurement will first orientate the drug design
on a family of interest; ESI-MS will then monitor the
effect of the chemical modifications introduced during
the drug design optimization phase, and will allow one
to select the compounds displaying the stronger elec-
trostatic and H-bond contacts with the target enzyme.
Finally, X-ray crystallography will analyze in detail the
geometry required to reach the best binding.
Conclusions
This paper describes the application of two different
techniques to the analysis of inhibitors binding to
aldose reductase: X-ray crystallography and mass spec-
trometry. These techniques may be applied in a drug
design process; after an initial IC50 screening has se-
lected the most adequate inhibitors and the drug design
cycle of chemical modification and efficacy test is en-
gaged.
The models built based on crystallographic data
provide a detailed description of the interatomic con-
tacts involved in ligand binding. However, the image is
static and there is no direct experimental measurement
of the energies involved: these energies need to be
inferred from the structure through modeling studies.
On the other hand, mass spectrometry, by measuring
the energy needed to dissociate 50% of the enzyme–
coenzyme–inhibitor complexes in the gas phase, pro-
vides a fast mean to detect the inhibitors which have the
strongest electrostatic and H-bond terms in the binding
energy. Our goal is therefore to exploit the sinergy of
both techniques in the optimization of new inhibitors.
However, some restrictions to this approach must be
emphasized: depending on the protein, the 3-D struc-
ture may be modified in vacuo to a more or less
important extent compared to the in-solution conforma-
tion, which may, for some cases, lead to the modifica-
tion of the active site geometry. Therefore, the applica-
bility of the method requires a preliminary verification
that the 3-D structure of the system is not severely
affected by the desorption in the gas phase, and, in any
case, caution will be needed in the use of mass spec-
trometry to predict binding energies beyond the most
stable core of the protein. Even if our study suggests
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that, in the case of aldose reductase, gas-phase stabili-
ties evaluated by mass spectrometry may be used to
measure the part of the binding energy due to the
specific electrostatic and H-bond contacts, further com-
parative studies by crystallography and mass spectrom-
etry on other systems are needed to confirm this result.
Finally, our results show that, in the general case, a
direct correlation between the gas-phase stabilities and
the binding affinities in solution should not be ex-
pected. Nevertheless, we hope that this paper has
convincingly demonstrated the perspectives offered by
gas-phase stability measurements in the investigation of
noncovalent biological complexes, in particular, in the
field of drug development.
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